Patent application number | Description | Published |
20080311170 | IMPLANT DEVICE RELEASE AGENTS AND METHODS OF USING SAME - Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm | 12-18-2008 |
20090035343 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 02-05-2009 |
20090087470 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 04-02-2009 |
20090098182 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. | 04-16-2009 |
20090208540 | IMPLANTABLE DEVICE FOR THE DELIVERY OF NALTREXONE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver naltrexone and formulations thereof at a constant rate for an extended period of time. The devices and methods of use thereof are biocompatible and biostable, and useful for the delivery of naltrexone in patients (humans and animals). | 08-20-2009 |
20090214634 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER - Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent. | 08-27-2009 |
20100021522 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 01-28-2010 |
20100022450 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 01-28-2010 |
20100080835 | IMPLANTABLE DEVICE FOR THE DELIVERY OF RISPERIDONE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs. | 04-01-2010 |
20100247594 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 09-30-2010 |
20100292144 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 11-18-2010 |
20100317579 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 12-16-2010 |
20110009338 | CONTROLLED RELEASE FORMULATIONS OF OCTREOTIDE - A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein. | 01-13-2011 |
20110034566 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:
| 02-10-2011 |
20110059147 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:
| 03-10-2011 |
20110184376 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE-BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. | 07-28-2011 |
20110206745 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 08-25-2011 |
20110236456 | IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs. | 09-29-2011 |
20110244015 | IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs. | 10-06-2011 |
20120114730 | COMPOSITIONS AND METHODS FOR TREATING PRECOCIOUS PUBERTY - The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP). | 05-10-2012 |
20120231061 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE-BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. | 09-13-2012 |
20130096496 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:
| 04-18-2013 |
20130144250 | IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS OF TREATMENT THEREOF - A method of treatment, such as treating an estrogen-related disorder or a psychotic disorder, by implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of an active pharmaceutical ingredient (such as an aromatase inhibitor or risperidone) to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes an active pharmaceutical ingredient and optionally, a sorption enhancer. | 06-06-2013 |
20130252894 | SUSTAINED DELIVERY OF EXENATIDE AND OTHER POLYPEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof. | 09-26-2013 |
20130302397 | IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs. | 11-14-2013 |
20130310740 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:
| 11-21-2013 |
20140012222 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE-BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. | 01-09-2014 |
20140135684 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises:
| 05-15-2014 |
20140349936 | COMPOSITIONS AND METHODS FOR TREATING PRECOCIOUS PUBERTY - The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP). | 11-27-2014 |